Pharma Focus Asia
KP - Choose our fully recyclable blister films

HaemaLogiX Enters into Agreement with Peter MacCallum Cancer Centre

Wednesday, July 26, 2023

HaemaLogiX and Peter MacCallum Cancer Centre have jointly entered into a co-development agreement to conduct the first in human Phase I trial of HaemaLogiX's CAR-T immunotherapy, KMA.CAR-T, for kappa-type multiple myeloma.

Under the collaborative agreement, HaemaLogiX will contribute its patented KappaMab technology to partner with Peter MacCallum Cancer Centre. Together, they aim to develop and establish a method of manufacturing, and jointly conduct the crucial Phase I trial for KMA.CAR-T in patients with kappa-type multiple myeloma.

This agreement comes after a successful collaborative preclinical research project that provided compelling evidence of the therapy's potential. In the preclinical research, KMA.CAR-T cells were tested against myeloma cell lines expressing the KMA antigen. The results demonstrated that the CAR-T cells specifically targeted and killed the KMA-expressing myeloma cells, indicating a selective and potent anti-myeloma activity of the therapy.

KMA.CAR-T is an innovative immunotherapy designed to treat kappa-type multiple myeloma, a form of cancer that affects plasma cells in the bone marrow. This therapy utilises CAR-T cell technology to target a specific receptor called Kappa Myeloma Antigen (KMA), which is unique to the surface of myeloma cells in patients with kappa-type multiple myeloma.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024